分子診斷合作與授權協議：2016-2024

Molecular Diagnostics Collaboration and Licensing Deals 2016-2024

出版日期: 2024年11月01日 | 出版商:

Current Partnering | 英文 400+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告審查了 2016 年至 2024 年與分子診斷相關的合作和許可協議，包括協議總數的趨勢、財務合約條款、活躍於協議中的主要公司的識別以及合約文件目錄等。

主要優點

您可以瞭解 2016 年以來的合約趨勢。
您可以查看合作夥伴關係和授權項目。
基準分析：您可以確定合約的市場價值
財務條款：一次性付款、里程碑、特許權使用費
合約目錄：依公司名稱 (A-Z)、合約類型及處理區域
重大合約：依合約金額
最活躍的合約公司
資產識別和每份合約的合約條款
取得合約文件：深入瞭解合約結構
盡職調查：評估擬議合約條款對合作夥伴公司的適用性
節省數百小時的研究時間

合約分析允許盡職調查：

授予或可選的具體權利有哪些？
合約實際上賦予了合作夥伴公司什麼？
授予哪些類型的專有權？
合約的付款結構為
如何審核銷售和付款？
合約期限是多久？
合約的主要條款是如何定義的？
如何對待和擁有知識產權？
誰負責商業化？
誰負責開發、供應和製造？
如何管理保密和發佈？
如何解決爭議
什麼情況下可以取消合約？
如果所有者發生變化會怎樣？
已就何種類型的分授權或分包條款達成協議？
公司需要哪些樣板條款？
哪些樣板條款看起來有所不同，取決於合作夥伴和交易類型？
每家公司對合約法擁有哪些管轄權？

This report contains a comprehensive listing of 747 molecular diagnostics deals announced since 2016 including financial terms where available including links to online deal records of actual molecular diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of molecular diagnostics dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in molecular diagnostics dealmaking since 2016.

Chapter 3 provides an overview of the leading molecular diagnostics deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in molecular diagnostics dealmaking with a brief summary followed by a comprehensive listing of molecular diagnostics deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of molecular diagnostics deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of molecular diagnostics partnering deals signed and announced since Jan 2016. The chapter is organized by specific molecular diagnostics technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in molecular diagnostics deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Molecular Diagnostics Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2016
Browse molecular diagnostics collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, deal type and therapy area
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Molecular Diagnostics Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of molecular diagnostics trends and structure of deals entered into by leading biopharma companies worldwide.

Molecular Diagnostics Collaboration and Licensing Deals includes:

Trends in molecular diagnostics dealmaking in the biopharma industry
Directory of molecular diagnostics deal records covering pharmaceutical and biotechnology
The leading molecular diagnostics deals by value
Most active molecular diagnostics licensing dealmakers
Molecular Diagnostics Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in molecular diagnostics dealmaking

2.1. Introduction
2.2. Molecular diagnostics deals over the years
2.3. Most active molecular diagnostics dealmakers
2.4. Molecular diagnostics deals by deal type
2.5. Molecular diagnostics deals by therapy area
2.6. Molecular diagnostics deals by industry sector
2.7. Deal terms for molecular diagnostics deals
- 2.7.1 Molecular diagnostics deals headline values
- 2.7.2 Molecular diagnostics deal upfront payments
- 2.7.3 Molecular diagnostics deal milestone payments
- 2.7.4 Molecular diagnostics royalty rates